gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FBIOHealthcarePharmaceuticals

Fortress Biotech, Inc. (FBIO)

$1.97+1.55%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.00▼ 18.03% in range
Nov 3, 2025Low $1.87 · High $4.38Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Fortress Biotech closed at $1.97 on Nov 4, up 1.55%, 55.0% below its 52-week closing high. Volume of 124.4K shares was 0.59× its 20-day average (below normal).

Split-adjusted performance: -3.9% over one month, -22.7% over six months, -19.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $18.72M, up 14.0% from a year earlier, with a net margin of -13.2%.

Short interest was 4.5M shares at the Oct 15 settlement, down 7.7% from the prior report (17.7% of float, 16.1 days to cover).

Market cap$65.7M33.4M shares
Revenue · quarter$18.7M+14.0% YoY
Diluted EPS$-0.08−117.8% YoY
P/E · TTM0.6×P/S 0.9×
Net margin-13.2%Gross 67.2%
Dividend yieldNone
52-week range1.87 – 4.38−55.0% from high
Volume124.4K0.59× 20-day avg
Volatility · 60d43.7%Annualised
Short % of float17.7%16.1 days to cover
Net cash$157.0MCash $196.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.5%1M −3.9%3M −28.9%6M −22.7%YTD −46.2%1Y −19.3%3Y +15.9%5Y −96.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum55
Revenue growth61
Net margin62
Value (low P/E)100
Size36

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.5M−7.7% vs prior
Days to cover16.1Settled Oct 15
% of float17.7%
Short vol. 10d43.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FBIOFortress Biotech$1.97+1.55%−22.7%+14.0%−13.2%0.6$65.7M
RANIRani Therapeutics Holdings$0.5728+3.06%−40.3%—−432.7%—$66.1MCompare
CINGCingulate$4.56−3.39%−14.4%———$66.3MCompare
CPIXCumberland Pharmaceuticals$4.44+3.02%+1.6%−56.3%−2569.0%—$66.5MCompare
TELOTelomir Pharmaceuticals$0.8750−3.85%−34.7%———$64.5MCompare
TENXTenax Therapeutics$1.81−1.63%−84.9%———$67.7MCompare
CRBPCorbus Pharmaceuticals Holdings$3.57−7.75%−67.3%———$69.0MCompare
QUCYQuantum Cyber N.V$0.7430+2.65%————$62.5MCompare
SPROSpero Therapeutics$1.07+2.88%−57.7%−100.0%—8.4$62.3MCompare

News about Fortress Biotech

All news →
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswire Inc. · Sep 8, 2026▲ Positive

Quick answers

What does Fortress Biotech do?
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products.
What is FBIO's market cap?
$65.70M, based on the Nov 4 close of $1.97.
What is FBIO's P/E ratio?
0.6× trailing-twelve-month earnings of $103.37M.
Does Fortress Biotech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FBIO is sold short?
4.5M shares, 17.7% of float, as of Oct 15, 2026.
What sector is FBIO in?
Healthcare, in the Pharmaceuticals industry.

About Fortress Biotech

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

HQ: Bay Harbor Islands, FL78 employeesListed Nov 17, 2011fortressbiotech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology